Want to see HK:2877 full AI Analyst Report?
Top Page
China Shineway Pharmaceutical Group Limited
(2877)
Select Model
Select Model
Rating:81Outperform
Price Target:
HK$9.50
â–²(11.50% Upside)
Action:Reiterated
Date:09/10/26
The score is driven primarily by strong financial quality (high margins and very low leverage) and attractive valuation (low P/E and high dividend yield). Technicals are supportive with the price above major moving averages, but the elevated RSI and recent revenue contraction temper the overall rating.
Positive Factors
Very Conservative Balance Sheet
Minimal leverage limits financial risk and interest burdens, while the substantial equity base supports resilience. Solid ROE indicates the company generates reasonable shareholder returns without depending heavily on borrowing.
Negative Factors
Revenue Contraction
Sustained revenue weakness signals softer demand, reduced prescription or healthcare-channel activity, or unfavorable product mix. Without a clear growth catalyst, lower sales can constrain operating leverage and weaken the longer-term earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Conservative Balance Sheet
Minimal leverage limits financial risk and interest burdens, while the substantial equity base supports resilience. Solid ROE indicates the company generates reasonable shareholder returns without depending heavily on borrowing.
Read all positive factors
China Shineway Pharmaceutical Group Limited (2877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.33B
Dividend Yield17.11%
Average Volume (3M)942.66K
Price to Earnings (P/E)6.8
Beta (1Y)0.52
Revenue Growth-17.74%
EPS Growth1.12%
CountryHK
Employees2,822
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.25
Shares Outstanding827,000,000
10 Day Avg. Volume1,956,699
30 Day Avg. Volume942,660
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.72
Price to Sales (P/S)1.86
P/FCF Ratio5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$3.03B
China Shineway Pharmaceutical Group Limited Business Overview & Revenue Model
Company Description
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product ...
How the Company Makes Money
China Shineway Pharmaceutical Group Limited makes money mainly by manufacturing and selling pharmaceutical products, with its revenue primarily generated from the sale of its proprietary modernized TCM products. The company’s key revenue streams a...
China Shineway Pharmaceutical Group Limited Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
90
Very Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.14B | 3.78B | 4.52B | 3.95B | 3.22B |
| Gross Profit | 2.27B | 2.83B | 3.39B | 2.94B | 2.41B |
| EBITDA | 739.52M | 1.00B | 1.42B | 1.10B | 903.74M |
| Net Income | 949.95M | 840.05M | 969.51M | 722.77M | 556.67M |
Balance Sheet | |||||
| Total Assets | 10.78B | 10.04B | 9.57B | 8.23B | 7.20B |
| Cash, Cash Equivalents and Short-Term Investments | 7.57B | 6.49B | 5.91B | 5.05B | 4.21B |
| Total Debt | 335.05M | 346.53M | 301.33M | 7.44M | 14.91M |
| Total Liabilities | 2.72B | 2.57B | 2.54B | 1.85B | 1.30B |
| Stockholders Equity | 8.07B | 7.47B | 7.03B | 6.38B | 5.90B |
Cash Flow | |||||
| Free Cash Flow | 974.13M | 823.02M | 788.31M | 980.21M | 609.52M |
| Operating Cash Flow | 1.17B | 963.13M | 932.63M | 1.11B | 703.15M |
| Investing Cash Flow | 222.03M | -272.11M | -49.54M | -45.42M | 395.01M |
| Financing Cash Flow | -375.01M | -392.48M | -26.74M | -250.04M | -828.93M |
China Shineway Pharmaceutical Group Limited Technical Analysis
Positive
8.52
Price Trends
7.21
Positive
7.44
Positive
7.57
Positive
Market Momentum
0.12
Negative
74.75
Negative
0.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2877, the sentiment is Positive. The current price of 8.52 is above the 20-day moving average (MA) of 7.29, above the 50-day MA of 7.21, and above the 200-day MA of 7.57, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 74.75 is Negative, neither overbought nor oversold. The STOCH value of 0.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2877.
China Shineway Pharmaceutical Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$6.33B | 6.76 | 9.81% | 17.11% | -17.74% | 1.12% | |
77 Outperform | HK$1.86B | 6.39 | 13.26% | 9.37% | -0.47% | -0.40% | |
70 Outperform | HK$16.67B | 26.04 | 3.09% | 3.53% | -12.86% | -83.10% | |
60 Neutral | HK$17.57B | 15.59 | 6.61% | 3.38% | 7.35% | -45.49% | |
53 Neutral | HK$6.72B | -5.43 | -4.98% | 0.26% | -15.80% | -298.94% | |
52 Neutral | HK$9.04B | 43.20 | 4.10% | 3.05% | 4.81% | -48.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2877
China Shineway Pharmaceutical Group Limited
8.30
0.85
11.36%
HK:3933
The United Laboratories International Holdings
8.47
-7.91
-48.31%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.31
-0.85
-39.35%
HK:2633
Jacobson Pharma Corporation Limited
0.97
-0.43
-30.87%
HK:0512
Grand Pharmaceutical Group Limited
5.00
-3.97
-44.31%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
5.66
-1.63
-22.37%
China Shineway Pharmaceutical Group Limited Corporate Events
China Shineway Board to Weigh Special Interim Dividend
Sep 8, 2026
China Shineway Pharmaceutical Group Limited has scheduled a board meeting for 18 September 2026 to consider declaring a special interim dividend for its shareholders. The move signals the company’s intention to return additional capital to i...
China Shineway Pharma Announces Second Interim Dividend for Fiscal 2026
Aug 27, 2026
China Shineway Pharmaceutical Group Limited, a Hong Kong-listed pharmaceutical company under stock code 02877, operates in the healthcare sector by issuing equity to investors in renminbi with corresponding Hong Kong dollar settlements. Its board ...
Shineway Profit Falls Amid TCM Headwinds but Dividend Payout Stays Strong
Aug 27, 2026
China Shineway reported a sharp deterioration in its interim performance for the six months ended 30 June 2026 as the TCM industry came under pressure from medical insurance cost controls, centralized procurement, weak terminal demand and destocki...
China Shineway to Review Interim Results and Consider Dividend at August Board Meeting
Aug 17, 2026
China Shineway Pharmaceutical Group Limited has scheduled a board meeting for 27 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The board will also consider the declaration of a dividend at the meeting...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.